Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
BörsenkürzelTIVC
Name des UnternehmensTivic Health Systems Inc
IPO-datumNov 11, 2021
CEOErnst (Jennifer)
Anzahl der mitarbeiter7
WertpapierartOrdinary Share
GeschäftsjahresendeNov 11
Addresse47685 Lakeview Blvd
StadtFREMONT
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94538
Telefon18882766888
Websitehttps://tivichealth.com/
BörsenkürzelTIVC
IPO-datumNov 11, 2021
CEOErnst (Jennifer)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten